NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms No drug interventions treatment 1 recruiting NCT05823571
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients treatment 1 recruiting NCT06265584
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant treatment 2 not_yet_recruiting NCT03977103
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT No drug interventions treatment 2 unknown_status NCT05842603
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients No drug interventions supportive_care Not Available recruiting NCT02580903
Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms No drug interventions Not Available Not Available completed NCT01728402
Pathogenesis of Hematologic Malignancies No drug interventions Not Available Not Available enrolling_by_invitation NCT03655145
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation No drug interventions treatment 3 unknown_status NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT06481345
Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM) No drug interventions Not Available Not Available active_not_recruiting NCT01200498
Study of SB939 in Subjects With Myelofibrosis treatment 2 completed NCT04631211
Thrombosomes® in Bleeding Thrombocytopenic Patients Study treatment 2 terminated NCT00943293
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies treatment 1 terminated NCT06315309
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant treatment 2 not_yet_recruiting NCT00852709
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias treatment 1 terminated NCT05088356
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft treatment 1 recruiting NCT02320656
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 No drug interventions basic_science Not Available unknown_status NCT00511537
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders No drug interventions Not Available Not Available completed NCT01787552
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF treatment 1 / 2 completed NCT02806375
PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis treatment 1 / 2 completed NCT00075816
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) No drug interventions treatment 3 completed NCT00185796
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD No drug interventions treatment 2 completed NCT04631458
Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis No drug interventions Not Available Not Available unknown_status NCT05001386
In Vitro Drug Sensitivity Testing of Fresh Human Samples No drug interventions other Not Available not_yet_recruiting NCT05825326
Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador No drug interventions Not Available Not Available completed NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT00873574
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT00522574
A Safety Study of XL019 in Adults With Myelofibrosis treatment 1 terminated NCT01134120
A Study in Myeloproliferative Disorders treatment 1 completed NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT01787162
Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases No drug interventions Not Available Not Available completed NCT00295880
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer No drug interventions treatment 1 / 2 terminated NCT01144780
Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry No drug interventions Not Available Not Available terminated NCT01392989
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders treatment 2 completed NCT00858572
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders treatment 1 completed NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplant supportive_care 2 terminated NCT01366612
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation treatment 3 terminated NCT00061581
Experimental Bone Marrow Transplant Protocol No drug interventions treatment 2 completed NCT00283114
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 completed NCT00146055
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT00745550
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis treatment 1 / 2 completed NCT01683123
Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT No drug interventions Not Available Not Available completed NCT00452023
Pegasys® in Patients With Myeloproliferative Diseases treatment 2 completed NCT00967343
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor No drug interventions prevention 2 / 3 terminated NCT00074490
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers treatment 2 terminated NCT05969821
Clonal Hematopoiesis of Immunological Significance No drug interventions Not Available Not Available not_yet_recruiting NCT06138587
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation treatment 1 recruiting NCT00038051
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies No drug interventions treatment 1 completed NCT02766153
Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal No drug interventions Not Available Not Available terminated NCT00787761
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer treatment 2 completed NCT00186342
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies No drug interventions treatment Not Available completed NCT00569842
Investigation of the Cylex® ImmuKnow® Assay No drug interventions Not Available Not Available completed NCT00827099
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer treatment 2 terminated NCT01135849
B-Receptor Signaling in Cardiomyopathy No drug interventions Not Available Not Available completed NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis treatment 1 / 2 active_not_recruiting NCT00578539
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE treatment Not Available terminated NCT02663648
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available withdrawn NCT00276926
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Not Available 2 unknown_status NCT00305682
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant treatment 2 completed NCT00186576
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders No drug interventions treatment Not Available completed NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 withdrawn NCT00361140
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) treatment 4 completed NCT00499668
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer supportive_care Not Available withdrawn NCT01413568
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 completed NCT04717414
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions treatment 3 active_not_recruiting NCT01684150
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving treatment 1 completed NCT00003838
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow treatment 2 completed NCT03808805
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms treatment 3 unknown_status NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention treatment 1 active_not_recruiting NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT03907436
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase No drug interventions treatment Not Available completed NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation treatment 2 active_not_recruiting NCT03869476
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. No drug interventions diagnostic Not Available recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT00687414
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders No drug interventions Not Available Not Available completed NCT03149055
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) treatment 2 completed NCT00175838
Primary Thrombocythaemia 1 Trial treatment Not Available completed NCT03688490
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms No drug interventions Not Available Not Available completed NCT05884333
Cord Blood Transplant in Adults With Blood Cancers No drug interventions treatment 2 recruiting NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies treatment Not Available completed NCT06246006
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia No drug interventions Not Available Not Available active_not_recruiting NCT01866839
Preventing Stem Cell Transplant Complications With a Blood Separator Machine No drug interventions treatment 1 / 2 completed NCT00588666
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma treatment 2 completed NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression treatment 3 active_not_recruiting NCT00909467
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases No drug interventions Not Available Not Available completed NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies treatment 2 completed NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT02720679
Investigation of the Genetics of Hematologic Diseases No drug interventions Not Available Not Available recruiting NCT01518153
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) treatment 2 terminated NCT00606307
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases treatment 2 completed NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT01444742
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT01375140
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis treatment 2 completed NCT02410551
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) treatment 2 terminated NCT02267278
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) treatment 2 completed NCT01875237
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene treatment 1 / 2 terminated NCT01800643
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation No drug interventions treatment 2 / 3 unknown_status NCT01749111
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis prevention 3 terminated NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT01167166
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) treatment 1 / 2 completed NCT02308787
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions No drug interventions Not Available Not Available completed NCT01884974
A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases. No drug interventions Not Available Not Available unknown_status NCT05553873
Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study. No drug interventions Not Available Not Available recruiting NCT01394640
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients No drug interventions Not Available Not Available completed NCT00665067
Correlative Biomarker Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation treatment 2 recruiting NCT04992949
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm No drug interventions treatment 2 recruiting NCT04968834
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy No drug interventions Not Available Not Available recruiting NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors treatment 1 recruiting NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT02873832
Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS) No drug interventions Not Available Not Available completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed